ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Alnylam Pharmaceuticals has selected Agilent Technologies to manufacture the active pharmaceutical ingredient for its RNAi therapeutic patisiran. Patisiran is an oligonucleotide targeting transthyretin for the treatment of the rare disease ATTR amyloidosis. Meanwhile, Scancell Holdings has signed up PolyPeptide Group, a contract manufacturer of therapeutic peptides, to make a peptide conjugate to Amplivant, an immuno-oncology drug Scancell is developing.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter